Format

Send to

Choose Destination
See comment in PubMed Commons below
Gene. 2014 Apr 25;540(1):1-10. doi: 10.1016/j.gene.2014.01.068. Epub 2014 Feb 8.

Matrix metalloproteinases and their role in psoriasis.

Author information

1
Vavilov Institute of General Genetics RAS, Gubkina str., Bld. 3, 119991 Moscow, Russia. Electronic address: mesentsev@yahoo.com.
2
Vavilov Institute of General Genetics RAS, Gubkina str., Bld. 3, 119991 Moscow, Russia. Electronic address: svarga2001@mail.ru.
3
Vavilov Institute of General Genetics RAS, Gubkina str., Bld. 3, 119991 Moscow, Russia. Electronic address: sergey.bruskin@gmail.com.

Abstract

This review summarizes the contribution of matrix metalloproteinases to the pathogenesis of psoriasis. In psoriasis, matrix metalloproteinases are involved in the structural changes of the epidermis via the modification of intracellular contacts and the composition of the extracellular matrix, promoting angiogenesis in the dermal blood vessels and the infiltration of immune cells. Moreover, some matrix metalloproteinases become differentially expressed during the disease eruption and their expression correlates with the clinical score. A separate section of the review is dedicated to the pharmacological approaches that are used to control matrix metalloproteinases, such as oral metalloproteinase inhibitors, such as azasugars and phosphonamides. The aim of this manuscript is to assess the role of matrix metalloproteinases in the physiological processes that accompany the disease. Moreover, it is especially important to evaluate progress in this field and characterize recently appeared medicines. Because any experimental drugs that target matrix metalloproteinases are involved in active clinical trials, this manuscript also reviews the latest experimental data regarding distribution and expression of matrix metalloproteinases in healthy skin and lesional skin. Therefore, the performed analysis highlights potential problems associated with the use of metalloproteinase inhibitors in clinical studies and suggests simple and easy understandable criteria that future innovative metalloproteinase inhibitors shall satisfy.

KEYWORDS:

Antidrug conception; Azasugars; Matrix metalloproteinases; Metalloproteinase inhibitors; Phosphonamides; Psoriasis

PMID:
24518811
DOI:
10.1016/j.gene.2014.01.068
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center